Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Treatment-Resistant OCD
NCT03983031Phase 1Completed
- Sponsor
- Region Örebro län
- Start
- Aug 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in obsessive compulsive disorder (OCD), sponsored by Region Örebro län. Primary endpoint: Yale-Brown Obsessive-Compulsive Scale at 20 weeks. Started Aug 2019; status: completed.
02
Drugs
rituximab
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT03983031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983031.